Clinical Trials & Research

Reviewed by Emily Henderson, B.Sc.Oct 1 2020 A new study led by researchers from Brigham and Women’s Hospital and the University of Minnesota, Minneapolis sheds light on why female primary care physicians receive lower wages than their male counterparts. The study found that female PCPs generated 11 percent less revenue due to conducting 11 percent
0 Comments
Print this page SEATTLE, Sept. 29, 2020 /PRNewswire/ – CTI BioPharma Corp. (Nasdaq: CTIC) today announced that following a recent Pre-NDA meeting with the U.S. Food and Drug Administration (“FDA” or “the Agency”), the Company has reached an agreement to submit an NDA for the potential accelerated approval of pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia (platelet count
0 Comments
Print this page September 25, 2020 — Interim analysis from the ongoing Phase 1/2a clinical trial of the Janssen COVID-19 vaccine candidate (JNJ-78436735) was posted today on the pre-print server medRxiv. The data demonstrate that a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants aged 18 years and older
0 Comments
Reviewed by Emily Henderson, B.Sc.Sep 26 2020 Criticisms of COVID-19 models by Democratic elites in May 2020 appeared to undermine public support for the models’ use – and trust in science more broadly – according to a series of survey experiments conducted with the participation of more than 6,000 Americans. However, whether Republican elites criticized
0 Comments
Print this page NEW BRUNSWICK, N.J., September 23, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies. The initiation of the ENSEMBLE trial follows positive interim results from the Company’s Phase 1/2a
0 Comments
Reviewed by Emily Henderson, B.Sc.Sep 25 2020 Clostridioides difficile, or C. diff, is the leading cause of health care-associated infection in the U.S. Only two antibiotics, vancomycin and fidaxomicin, are FDA approved for the treatment of C. diff, but even these therapies suffer from high treatment failure and recurrence. Now, Purdue University innovators have advanced
0 Comments
Print this page TOKYO — September 23, 2020 FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada; hereinafter “FUJIFILM Toyama Chemical”) has announced today that primary endpoint has been met in phase III clinical trial of “Avigan Tablet” (generic name: favipiravir, “Avigan”) conducted in Japan for patients with novel coronavirus infections (hereinafter “COVID-19”). The efficacy primary
0 Comments
Sep 23 2020 OXGENE™, a biotechnology company designing and developing scalable gene therapy technologies, has today announced the launch of its scalable, plasmid-free manufacturing system for AAV. OXGENE’s new TESSA™ technology addresses industry-wide challenges associated with robust and reproducible AAV manufacture at scale. These include high cost of goods, and low packaging efficiency. TESSA aims
0 Comments
Print this page Tokyo, Basking Ridge, N.J. and Munich – (September 14, 2020) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the first patient has been dosed in a phase 2 study evaluating patritumab deruxtecan (U3-1402), a HER3 directed DXd antibody drug conjugate (ADC), in patients with advanced or metastatic colorectal cancer who
0 Comments
Print this page INDIANAPOLIS, Sept. 14, 2020 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today initial data emerging from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). ACTT-2 included more than 1,000 patients and began
0 Comments
Print this page INDIANAPOLIS, Sept. 16, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced proof of concept data from an interim analysis of the BLAZE-1 clinical trial, showing a reduced rate of hospitalization for patients treated with LY-CoV555. The randomized, double-blind, placebo-controlled Phase 2 study evaluated LY-CoV555, a SARS-CoV-2 neutralizing antibody, for the treatment
0 Comments
After screening more than 3,500 FDA-approved drugs and small molecules, researchers at the Chinese Academy of Sciences found that ceftazidime, an antibiotic approved for use in treating pneumonia, binds to the receptors that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to in human cells. This drug could potentially be used to prevent virus
0 Comments
Print this page HAMILTON, Bermuda, Sept. 15, 2020 (GLOBE NEWSWIRE) – Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to mavrilimumab for the treatment of giant cell arteritis (GCA). Mavrilimumab
0 Comments
Print this page London, UK and Paris, France 03 September 2020 — Sanofi and GSK announce today the start of the Phase 1/2 clinical trial for their adjuvanted COVID-19 vaccine. The vaccine candidate, developed in partnership by Sanofi and GSK, uses the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines with GSK’s
0 Comments
Reviewed by Emily Henderson, B.Sc.Sep 12 2020 Cornell food scientists show in animal studies that a mother’s high-fat diet may lead to more sweet-taste receptors and a greater attraction to unhealthy food in their offspring – resulting in poor feeding behavior, obesity in adulthood. The researchers’ findings were published July 31 in Scientific Reports. Maternal
0 Comments
Print this page KENILWORTH, N.J.–(BUSINESS WIRE) September 8, 2020 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced the results from two pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and safety of gefapixant (MK-7264), an investigational, orally administered, selective P2X3 receptor antagonist, for the potential treatment
0 Comments
Print this page 09 September 2020 — As part of the ongoing randomised, controlled clinical trials of the AstraZeneca Oxford coronavirus vaccine, AZD1222, a standard review process has been triggered, leading to the voluntary pause of vaccination across all trials to allow an independent committee to review the safety data of a single event of an unexplained
0 Comments
Print this page TARRYTOWN, N.Y., Aug. 19, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine (NEJM) published positive results from the Phase 3 trial of evinacumab in 65 patients with homozygous familial hypercholesterolemia (HoFH). Evinacumab is an investigational medicine that binds to and blocks the function of angiopoietin-like 3 (ANGPTL3), and is
0 Comments
Reviewed by Emily Henderson, B.Sc.Sep 7 2020 Patients with autoimmune inflammation of their thyroid may be at greater risk of developing anxiety, according to a study being presented at e-ECE 2020. The study found that people with anxiety may also have inflammation in their thyroid gland that can be reduced by taking the non-steroidal anti-inflammatory,
0 Comments
Print this page NEW YORK and MAINZ, Germany, Aug. 20, 2020 (GLOBE NEWSWIRE) —  Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today shared additional Phase 1 safety and immunogenicity data from their ongoing U.S. study of the BNT162 mRNA-based vaccine program against SARS-CoV-2, which has advanced into Phase 2/3 evaluation. The newly released manuscript describes key
0 Comments
Reviewed by Emily Henderson, B.Sc.Sep 4 2020 In contrast to WHO´s and other expert´s advice, the worst-off countries should be extra prioritised when it comes to COVID-19 vaccine allocation, according to Professor Ole Frithjof Norheim at the University of Bergen. Once effective COVID-19 vaccines are approved, they will be scarce. WHO and others have promised
0 Comments
Print this page CAMBRIDGE, Mass.–(BUSINESS WIRE)– September 2, 2020 — Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases, today announced the publication of results from the pivotal CENTAUR trial evaluating AMX0035 – an investigational neuroprotective therapy designed to reduce the death
0 Comments